Breaking News

Tasly Pharma Selects ICON for Global Phase III Trial

Will also provide IVRS, data management and central lab services for trials

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

ICON plc, has been selected by Tasly Pharmaceuticals to conduct a global Phase III trial for T89, a botanical product being studied for the treatment of chronic stable angina pectoris due to coronary heart disease. The drug is also known as DantonicÒ pill, and, if approved, would be the first traditional Chinese medicine to gain FDA approval.   Tasly is conducting two global Phase III trials for the DantonicÒ pill and ICON has been awarded the three-arm Phase III trial and will also be providing...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters